Skip to main content Accessibility help
Hostname: page-component-848d4c4894-p2v8j Total loading time: 0.001 Render date: 2024-05-25T08:11:03.154Z Has data issue: false hasContentIssue false

Chapter 8 - Gonadotropins in Ovarian Stimulation

from Section 2 - Ovarian Hyperstimulation for IVF

Published online by Cambridge University Press:  14 April 2022

Mohamed Aboulghar
University of Cairo IVF Centre
Botros Rizk
University of South Alabama
Get access


Follicle-stimulating hormone (FSH)-containing gonadotropin preparations have been commercially available since the 1960s. Their first use was in ovulation induction in women with anovulatory disorders. Since 1978, however, after the first in vitro fertilization (IVF) baby was born, they have been used increasingly in assisted reproductive technologies (ART) such as IVF or intracytoplasmic sperm injection (ICSI) but also in intrauterine insemination (IUI) as ovarian stimulation to achieve multifollicular growth. Now, in many countries, ovulation induction stimulation comprises only 10% of gonadotropin usage, while 90% is used for ovarian (hyper) stimulation in ART, of which about half of the gonadotropin usage is for IVF and the other half is used for stimulated IUI cycles.

Publisher: Cambridge University Press
Print publication year: 2022

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)


Gemzell, CA, Diczfalusy, E, Tillinger, G. Clinical effect of human pituitary follicle-stimulating hormone (FSH). J Clin Endocrinol Metab 1958;18:13331348.Google Scholar
Bettendorf, S. Human hypophyseal gonadotropin in hypophysectomized women. Int J Fertil 1963;45:799809.Google Scholar
Cochius, JI, Mack, K, Burns, RJ. Creutzfeld–Jakob disease in a recipient human pituitary derived gonadotrophin. Aust N Z J Med 1990;20:592596.CrossRefGoogle Scholar
Dumble, LD, Klein, RD. Creutzfeld-Jakob disease legacy for Australian women treated with human pituitary gonadotropins. Lancet 1992;330:848.Google Scholar
Lunenfeld, B, Menzi, A, Insler, V. Effeti clinicci della gonadotropina umana della post-menopausa. Rass Clin Terap 1960;59:213216.Google Scholar
Lunenfeld, B. Treatment of anovulation by human gonadotrophins. J Int Fedn Gynecol Obstet 1963;1:153.Google Scholar
Biffoni, M, Battaglia, A, Borrelli, F, et al. Allergenic potential of gonadotrophic preparations in experimental animals: relevance of purity. Hum Reprod 1994;9:18451848.CrossRefGoogle ScholarPubMed
Biffoni, M, Marcucci, I, Ythier, A, Eshkol, A. Effects of urinary gonadotrophin preparations on human in-vitro immune function. Hum Reprod 1998;13:24302434.Google Scholar
Lunenfeld, B, Eshkol, A. Immunology of follicle stimulating hormone and luteinizing hormone. Vitam Horm 1970;27:131159.Google Scholar
Balen, AH, Hayden, CJ, Rutherford, AJ. What are the clinical benefits of recombinant gonadotrophins? Clinical efficacy of recombinant gonadotrophins. Hum Reprod 1999;14:14111417.Google Scholar
World Health Organization. Agents stimulating gonadal function in human. Report of a WHO scientific group. World Health Organization Tech Rep Ser 514. Geneva: World Health Organization; 1973.Google Scholar
Reichl, H, Balen, A, Jansen, CA. Prion transmission in blood and urine: what are the implications for recombinant and urinary-derived gonadotrophins? Hum Reprod 2002;17:25012508.Google Scholar
Serban, A, Legname, G, Hansen, K, Kovaleva, N, Prusiner, SB. Immunoglobulins in urine of hamsters with scrapie. J Biol Chem 2004;279:4881748820.Google Scholar
Shaked, GM, Shaked, Y, Kariv-Inbal, Z, et al. A protease-resistant prion protein isoform is present in urine of animals and humans affected with prion diseases. J Biol Chem 2001;276:3147931482.CrossRefGoogle ScholarPubMed
Hull, M, Corrigan, E, Piazzi, A, Loumaye, E. Recombinant human luteinising hormone: an effective new gonadotropin preparation. Lancet 1994;344:334335.CrossRefGoogle ScholarPubMed
Abd-Elaziz, K, Duijkers, I, Stöckl, L, et al. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials. Hum Reprod 2017;32(8):16391647.Google Scholar
Hård, K, Mekking, A, Damm, JB, et al. Isolation and structure determination of the intact sialylated N-linked carbohydrate chains of recombinant human follitropin expressed in Chinese hamster ovary cells. Eur J Biochem 1990;193:263271.Google Scholar
Creus, S, Chaia, Z, Pellizzari, EH, et al. Human FSH isoforms: carbohydrate complexity as determinant of in-vitro bioactivity. Mol Cell Endocrinol 2001;174:4149.Google Scholar
Timossi, CM, Barrios-de-Tomasi, J, González-Suárez, R, et al. Differential effects of the charge variants of human follicle-stimulating hormone. J Endocrinol 2000;165:193205.CrossRefGoogle ScholarPubMed
Ulloa-Aguirre, A, Timossi, C. Biochemical and functional aspects of gonadotrophin-releasing hormone and gonadotrophins. Reprod Biomed Online 2000;1:4862.CrossRefGoogle ScholarPubMed
Ulloa-Aguirre, A, Timossi, C, Barrios-de-Tomasi, J, Maldonado, A, Nayudu, P. Impact of carbohydrate heterogeneity in function of follicle-stimulating hormone: studies derived from in vitro and in vivo models. Biol Reprod 2003;69:379389.Google Scholar
Ulloa-Aguirre, A, Zambrano, E, Timossi, C, et al. On the nature of the follicle-stimulating signal delivered to the ovary during exogenously controlled follicular maturation. A search into the immunological and biological attributes and the molecular composition of two preparations of urofollitropin. Arch Med Res 1995;26 Spec No:S219S230.Google Scholar
Yding Andersen, C, Leonardsen, L, Ulloa-Aguirre, A, et al. FSH-induced resumption of meiosis in mouse oocytes: effect of different isoforms. Mol Hum Reprod 1999;5:726731.Google Scholar
Yding Andersen, CY, Leonardsen, L, Ulloa-Aguirre, A, et al. Effect of different FSH isoforms on cyclic-AMP production by mouse cumulus-oocyte-complexes: a time course study. Mol Hum Reprod 2001;7:129135.Google Scholar
Yding Andersen, C. Effect of FSH and its different isoforms on maturation of oocytes from pre-ovulatory follicles. Reprod Biomed Online 2002;5:232239.Google Scholar
Lambert, A, Rodgers, M, Mitchell, R, et al. In-vitro biopotency and glycoform distribution of recombinant human follicle stimulating hormone (Org 32489), Metrodin and Metrodin-HP Hum Reprod 1995;10:19281935.CrossRefGoogle ScholarPubMed
Andersen, CY, Westergaard, LG, van Wely, M. FSH isoform composition of commercial gonadotrophin preparations: a neglected aspect? Reprod Biomed Online 2004;9:231236.Google Scholar
Dias, JA, Ulloa-Aguirre, A. New human follitropin preparations: how glycan structural differences may affect biochemical and biological function and clinical effect. Front Endocrinol (Lausanne) 2021;12:636038. doi: 10.3389/fendo.2021.636038.Google Scholar
Deeks, JJ, Higgins, JPT, Altman, DG (eds.). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins, JPT, Thomas, J, Chandler, J, et al., eds. Cochrane Handbook for Systematic Reviews of Interventions, version 6.2 (updated February 2021). Cochrane; 2021.Google Scholar
Daya, S, Gunby, J, Hughes, EG, Collins, JA, Sagle, MA. Follicle-stimulating hormone versus human menopausal gonadotropin for in vitro fertilization cycles: a meta-analysis. Fertil Steril 1995;64:347354.Google Scholar
Agrawal, R, Holmes, J, Jacobs, HS. Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis. Fertil Steril 2000;73:338343.Google Scholar
van Wely, M, Kwan, I, van der Veen, F, et al. Recombinant FSH versus urinary gonadotrophins for ovarian hyperstimulation in IVF or ICSI cycles. A systematic review and meta-analysis. Hum Reprod 2009;24:S1, i134.Google Scholar
Bordewijk, EM, Mol, F, van der Veen, F, van Wely, M. Required amount of rFSH, HP-hMG and HP-FSH to reach a live birth. A systematic review and meta-analysis. Hum Reprod Open 2019; 2019(3): hoz008. Scholar
Mochtar, MH, Danhof, NA, Ayeleke, RO, Van der Veen, F, van Wely, M. Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ ICSI cycles. Cochrane Database Syst Rev 2017;5: CD005070.Google ScholarPubMed
Lensen, SF, Wilkinson, J, Leijdekkers, JA, et al. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI). Cochrane Database Syst Rev 2018;2:CD012693.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the or variations. ‘’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats